Merus Labs International Inc. (TSE:MSL – Free Report) (NASDAQ:MSLI) – HC Wainwright cut their FY2024 earnings per share (EPS) estimates for Merus Labs International in a research note issued to investors on Monday, November 18th. HC Wainwright analyst A. He now expects that the specialty pharmaceutical company will earn ($0.24) per share for the year, down from their prior estimate of ($0.20). HC Wainwright also issued estimates for Merus Labs International’s FY2027 earnings at ($0.25) EPS.
Merus Labs International Stock Performance
The company’s 50 day moving average price is C$1.65. Merus Labs International has a 52-week low of C$0.95 and a 52-week high of C$1.76.
Merus Labs International Company Profile
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Read More
- Five stocks we like better than Merus Labs International
- How to Capture the Benefits of Dividend Increases
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- What is the Hang Seng index?
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- Using the MarketBeat Dividend Tax Calculator
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Merus Labs International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International and related companies with MarketBeat.com's FREE daily email newsletter.
